A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), may be able to effectively replace more complicated HIV treatment regimens used by ...

Feb 25 (Reuters) - Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well ...

People who have lived with HIV long-term can need up to a dozen pills every day to suppress the virus. Results from a new ...

Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...

As GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV prevention and treatment field, the company is reinforcing the staying power of its long-acting treatment Cabenuva | ...

Zimbabwe is one of the world's first countries to roll out lenacapavir, a long-acting HIV prevention drug that is ...

While medical breakthroughs have made ending HIV transmission a realistic goal, experts warn that stigma and misinformation ...

The Philadelphia HIV Resource Finder allows Philadelphians to search for treatment and prevention resources throughout the city.

Development assistance for health has fallen back toward 2010 levels, disproportionately disrupting community-based HIV services and projecting increased infections and AIDS-related deaths.

TACLOBAN CITY – The island town of Biri in Northern Samar has opened an HIV Treatment Hub to strengthen healthcare service ...